The outcomes for newly diagnosed advanced mesothelioma were further improved with the addition of the VEGF inhibitor bevacizumab to cisplatin/pemetrexed in the Phase III Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS). This evidence concerns the gene VEGFA and mesothelioma.